Home
/
GT Biopharma, Inc.
/
Financials
/
Quarterly
GT Biopharma, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that GT Biopharma, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2021
Sep 30, 2021
$0
Nov 10, 2021
Q2
2021
Jun 30, 2021
$0
Dec 29, 2021
Q1
2021
Mar 31, 2021
$0
May 17, 2021
Q3
2021
Sep 30, 2020
$0
Nov 10, 2021
Q2
2021
Jun 30, 2020
$0
Dec 29, 2021
Q1
2021
Mar 31, 2020
$0
May 17, 2021
Q1
2020
Mar 31, 2019
$0
May 15, 2020
Q2
2018
Jun 30, 2018
$0
Aug 14, 2018
Q1
2019
Mar 31, 2018
$0
May 15, 2019
Q2
2018
Jun 30, 2017
$0
Aug 14, 2018
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q1
2018
Mar 31, 2018
$0
May 15, 2018
Q3
2017
Sep 30, 2017
$0
Nov 14, 2017
Q2
2017
Jun 30, 2017
$0
Aug 11, 2017
Q1
2018
Mar 31, 2017
$0
May 15, 2018
Q3
2016
Sep 30, 2016
$0
Feb 28, 2018
Q2
2016
Jun 30, 2016
$0
Feb 28, 2018
Q1
2016
Mar 31, 2016
$0
Feb 28, 2018
Q3
2016
Sep 30, 2015
$0
Feb 28, 2018
Q2
2016
Jun 30, 2015
$20.0K
Feb 28, 2018
Q1
2016
Mar 31, 2015
$7.0K
Feb 28, 2018
Q3
2015
Sep 30, 2014
$3.0K
Nov 13, 2015
Q2
2015
Jun 30, 2014
$25.0K
Aug 14, 2015
Q1
2015
Mar 31, 2014
$0
May 14, 2015
Q3
2013
Sep 30, 2013
$183.0K
Dec 17, 2014
Q2
2014
Jun 30, 2013
$56.0K
Jan 8, 2015
Q3
2014
Jun 30, 2013
$183.0K
Jan 8, 2015
Q1
2014
Mar 31, 2013
$88.0K
Jan 8, 2015
Q3
2013
Sep 30, 2012
$120.0K
Dec 17, 2014
Q2
2013
Jun 30, 2012
$1.0K
Dec 12, 2014
Q1
2013
Mar 31, 2012
$1.0K
Dec 10, 2014
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$8.30M
Mar 6, 2026
Q2
2025
Jun 30, 2025
($30.17M)
Mar 6, 2026
Q1
2025
Mar 31, 2025
($776.0K)
May 15, 2025
Q3
2025
Sep 30, 2024
($3.41M)
Mar 6, 2026
Q2
2025
Jun 30, 2024
($3.71M)
Mar 6, 2026
Q1
2025
Mar 31, 2024
($2.27M)
May 15, 2025
Q3
2024
Sep 30, 2023
($2.42M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($1.99M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($227.0K)
May 15, 2024
Q3
2023
Sep 30, 2022
($6.88M)
Nov 1, 2023
Q2
2023
Jun 30, 2022
($2.98M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($5.44M)
May 15, 2023
Q3
2022
Sep 30, 2021
($5.45M)
Oct 31, 2022
Q2
2022
Jun 30, 2021
($4.86M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($29.68M)
May 16, 2022
Q3
2021
Dec 31, 2020
($2.88M)
Nov 10, 2021
Q3
2021
Sep 30, 2020
($2.88M)
Nov 10, 2021
Q2
2021
Jun 30, 2020
($17.42M)
Dec 29, 2021
Q1
2021
Mar 31, 2020
($1.71M)
May 17, 2021
Q3
2020
Sep 30, 2019
($29.88M)
Nov 13, 2020
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($3.38M)
Mar 6, 2026
Q2
2025
Jun 30, 2025
($1.51M)
Mar 6, 2026
Q1
2025
Mar 31, 2025
($1.93M)
May 15, 2025
Q3
2025
Sep 30, 2024
($3.60M)
Mar 6, 2026
Q2
2025
Jun 30, 2024
($3.91M)
Mar 6, 2026
Q1
2025
Mar 31, 2024
($3.09M)
May 15, 2025
Q3
2024
Sep 30, 2023
($3.12M)
Nov 14, 2024
Q2
2024
Jun 30, 2023
($3.62M)
Aug 14, 2024
Q1
2024
Mar 31, 2023
($3.67M)
May 15, 2024
Q3
2023
Sep 30, 2022
($7.02M)
Nov 1, 2023
Q2
2023
Jun 30, 2022
($3.01M)
Aug 7, 2023
Q1
2023
Mar 31, 2022
($5.44M)
May 15, 2023
Q3
2022
Sep 30, 2021
($5.95M)
Oct 31, 2022
Q2
2022
Jun 30, 2021
($4.38M)
Aug 15, 2022
Q1
2022
Mar 31, 2021
($29.00M)
May 16, 2022
Q3
2020
Sep 30, 2020
($1.95M)
Nov 13, 2020
Q2
2020
Jun 30, 2020
($1.56M)
Aug 18, 2020
Q1
2021
Mar 31, 2020
$1.07M
May 17, 2021
Q3
2020
Sep 30, 2019
($8.86M)
Nov 13, 2020
Q2
2020
Jun 30, 2019
($2.28M)
Aug 18, 2020